secwatch.observer — SEC 8-K summary
======================================

Issuer:     ASSEMBLY BIOSCIENCES, INC. (ASMB)
CIK:        0001426800
Form:       8-K
Filed at:   2024-12-19T23:59:59+00:00
Accession:  0000950170-24-138242
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Assembly Bio receives $10M from Gilead, Gilead buys 940,499 shares at $21.37
----------------------------------------------------------------------------

- Gilead pays $10M upfront payment creditable against future collaboration obligations.
- Opt-in fees for ABI-6250 restructured; total aggregate payments unchanged.
- Gilead purchases 940,499 shares at $21.37/share, a 35% premium to 30-day VWAP.
- Amendment redefines Phase 1b clinical trial and Triggering Clinical Trial for certain programs.
- Additional Funding Payment of $10M due within [***] days; use restricted per Section 15.5(a).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1426800/000095017024138242/0000950170-24-138242-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1426800/000095017024138242/asmb-20241219.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-138242

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer